- Home
- TLSI vs ENTA Comparison
TLSI vs ENTA Comparison
Compare TLSI & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- ENTA
- Stock Information
- Founded
- TLSI 2010
- ENTA 1995
- Country
- TLSI United States
- ENTA United States
- Employees
- TLSI N/A
- ENTA N/A
- Industry
- TLSI Medical Specialities
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- ENTA Health Care
- Exchange
- TLSI Nasdaq
- ENTA Nasdaq
- Market Cap
- TLSI 150.0M
- ENTA 164.6M
- IPO Year
- TLSI N/A
- ENTA 2013
- Fundamental
- Price
- TLSI $3.94
- ENTA $7.60
- Analyst Decision
- TLSI Strong Buy
- ENTA Strong Buy
- Analyst Count
- TLSI 5
- ENTA 4
- Target Price
- TLSI $10.90
- ENTA $20.75
- AVG Volume (30 Days)
- TLSI 73.5K
- ENTA 175.4K
- Earning Date
- TLSI 08-12-2025
- ENTA 08-11-2025
- Dividend Yield
- TLSI N/A
- ENTA N/A
- EPS Growth
- TLSI N/A
- ENTA N/A
- EPS
- TLSI N/A
- ENTA N/A
- Revenue
- TLSI $35,990,000.00
- ENTA $64,806,000.00
- Revenue This Year
- TLSI $55.39
- ENTA N/A
- Revenue Next Year
- TLSI $54.89
- ENTA $4.05
- P/E Ratio
- TLSI N/A
- ENTA N/A
- Revenue Growth
- TLSI 45.50
- ENTA N/A
- 52 Week Low
- TLSI $3.42
- ENTA $4.09
- 52 Week High
- TLSI $6.04
- ENTA $13.43
- Technical
- Relative Strength Index (RSI)
- TLSI 39.84
- ENTA 52.98
- Support Level
- TLSI $3.42
- ENTA $6.45
- Resistance Level
- TLSI $4.00
- ENTA $7.73
- Average True Range (ATR)
- TLSI 0.36
- ENTA 0.50
- MACD
- TLSI -0.01
- ENTA -0.02
- Stochastic Oscillator
- TLSI 34.75
- ENTA 54.57
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.